An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154 on ClinicalTrials.gov · last registry update 2020-10-30

Stopped early, having planned 4 participants. The sponsor logged completion for 16 March 2017. Primary outcome, as filed: Part A: Distribution of Average Power by Frequency Region. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 4
Started: 2016-09-26
Primary completion: 2017-03-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Part A: Distribution of Average Power by Frequency Region

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.